These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 12423799)

  • 1. Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria.
    Héchard Y; Sahl HG
    Biochimie; 2002; 84(5-6):545-57. PubMed ID: 12423799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial mechanism of lantibiotics.
    Islam MR; Nagao J; Zendo T; Sonomoto K
    Biochem Soc Trans; 2012 Dec; 40(6):1528-33. PubMed ID: 23176511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
    Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
    Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.
    Hasper HE; Kramer NE; Smith JL; Hillman JD; Zachariah C; Kuipers OP; de Kruijff B; Breukink E
    Science; 2006 Sep; 313(5793):1636-7. PubMed ID: 16973881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the targeted membrane pore formation mechanism by solution NMR: the nisin Z and lipid II interaction in SDS micelles.
    Hsu ST; Breukink E; de Kruijff B; Kaptein R; Bonvin AM; van Nuland NA
    Biochemistry; 2002 Jun; 41(24):7670-6. PubMed ID: 12056898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
    Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
    Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
    Bonelli RR; Schneider T; Sahl HG; Wiedemann I
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of lipid II-targeting lantibiotics.
    Bauer R; Dicks LM
    Int J Food Microbiol; 2005 May; 101(2):201-16. PubMed ID: 15862882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics.
    Brötz H; Josten M; Wiedemann I; Schneider U; Götz F; Bierbaum G; Sahl HG
    Mol Microbiol; 1998 Oct; 30(2):317-27. PubMed ID: 9791177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity.
    Wiedemann I; Breukink E; van Kraaij C; Kuipers OP; Bierbaum G; de Kruijff B; Sahl HG
    J Biol Chem; 2001 Jan; 276(3):1772-9. PubMed ID: 11038353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding role of lipid II as a target for lantibiotics.
    Martin NI; Breukink E
    Future Microbiol; 2007 Oct; 2(5):513-25. PubMed ID: 17927474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo cluster formation of nisin and lipid II is correlated with membrane depolarization.
    Tol MB; Morales Angeles D; Scheffers DJ
    Antimicrob Agents Chemother; 2015; 59(6):3683-6. PubMed ID: 25870072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidation of the antimicrobial mechanism of mutacin 1140.
    Smith L; Hasper H; Breukink E; Novak J; Cerkasov J; Hillman JD; Wilson-Stanford S; Orugunty RS
    Biochemistry; 2008 Mar; 47(10):3308-14. PubMed ID: 18266322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriocins: mechanism of membrane insertion and pore formation.
    Moll GN; Konings WN; Driessen AJ
    Antonie Van Leeuwenhoek; 1999; 76(1-4):185-98. PubMed ID: 10532378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
    de Kruijff B; van Dam V; Breukink E
    Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranslationally modified bacteriocins--the lantibiotics.
    Guder A; Wiedemann I; Sahl HG
    Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5.
    Paiva AD; Breukink E; Mantovani HC
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5284-93. PubMed ID: 21876041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assembly and stability of nisin-lipid II pores.
    Hasper HE; de Kruijff B; Breukink E
    Biochemistry; 2004 Sep; 43(36):11567-75. PubMed ID: 15350143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid II as a target for antibiotics.
    Breukink E; de Kruijff B
    Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple activities in lantibiotics--models for the design of novel antibiotics?
    Pag U; Sahl HG
    Curr Pharm Des; 2002; 8(9):815-33. PubMed ID: 11945173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.